276 lines
76 KiB
Text
276 lines
76 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK595311">
|
|
<meta name="ncbi_domain" content="niceng231er6">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK595311/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for frequency and duration of endoscopic surveillance - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for frequency and duration of endoscopic surveillance - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence review for frequency and duration of endoscopic surveillance">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2023/02">
|
|
<meta name="citation_pmid" content="37792979">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK595311/">
|
|
<meta name="citation_keywords" content="Barrett Esophagus">
|
|
<meta name="citation_keywords" content="Esophageal Neoplasms">
|
|
<meta name="citation_keywords" content="Endoscopy, Gastrointestinal">
|
|
<meta name="citation_keywords" content="Diagnosis">
|
|
<meta name="citation_keywords" content="Duration of Therapy">
|
|
<meta name="citation_keywords" content="Quality of Life">
|
|
<meta name="citation_keywords" content="Symptom Assessment">
|
|
<meta name="citation_keywords" content="Precancerous Conditions| Adolescent">
|
|
<meta name="citation_keywords" content="Young Adult">
|
|
<meta name="citation_keywords" content="Adult">
|
|
<meta name="citation_keywords" content="Middle Aged">
|
|
<meta name="citation_keywords" content="Aged">
|
|
<meta name="citation_keywords" content="Aged, 80 and over">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for frequency and duration of endoscopic surveillance">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2023/02">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK595311/">
|
|
<meta name="og:title" content="Evidence review for frequency and duration of endoscopic surveillance">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK595311/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng231er6-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng231er6/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK595311/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8ED09E7D6C8FE10000000000D900B7.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK595311/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK595311/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK595311/&text=Evidence%20review%20for%20frequency%20and%20duration%20of%20endoscopic%20surveillance"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK595311/?report=classic">Switch to classic view</a><a href="/books/n/niceng231er6/pdf/">PDF (551K)</a><a href="/books/n/niceng231er6/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK595311%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8ED09E7D6C8FE10000000000D900B7.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng231er6-lrg.png" alt="Cover of Evidence review for frequency and duration of endoscopic surveillance" /></a></div><div class="bkr_bib"><h1 id="_NBK595311_"><span itemprop="name">Evidence review for frequency and duration of endoscopic surveillance</span></h1><div class="subtitle">Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma</div><p><b>Evidence review F</b></p><p><i>NICE Guideline, No. 231</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2023 Feb</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-5012-6</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2023.</div></div><div class="bkr_clear"></div></div><div id="niceng231er6.s1"><h2 id="_niceng231er6_s1_">1. Frequency and duration of endoscopic surveillance</h2><div id="niceng231er6.s1.1"><h3>1.1. Review question</h3><p>What is the optimal frequency and duration of endoscopic surveillance for adults with Barrett’s oesophagus?</p><div id="niceng231er6.s1.1.1"><h4>1.1.1. Introduction</h4><p>Endoscopic surveillance for Barrett’s oesophagus is a resource intensive area for gastroenterology in the UK, and the frequency and duration is therefore of great importance as too much surveillance would result in patients undergoing unnecessary procedures, while too little surveillance would result in delays in cancer detection and reduced cancer prevention. Current UK practice is for endoscopy every 2 to 3 years for long segment Barrett’s and 3-5 yearly for short segment Barrett’s, with risk factors including smoking and family history determining precise intervals for individuals. Duration of surveillance is determined by whether the patient would continue to benefit, contingent on fitness to undergo and benefit from endoscopic procedures which would be necessary should a neoplastic lesion be discovered. These guidelines which are similar to European and US ones, are based largely on expert opinion in the absence of hard evidence.</p></div><div id="niceng231er6.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><p>For full details see the review protocol in <a href="#niceng231er6.appa">Appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng231er6tab1"><a href="/books/NBK595311/table/niceng231er6.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng231er6tab1" rid-ob="figobniceng231er6tab1"><img class="small-thumb" src="/books/NBK595311/table/niceng231er6.tab1/?report=thumb" src-large="/books/NBK595311/table/niceng231er6.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng231er6.tab1"><a href="/books/NBK595311/table/niceng231er6.tab1/?report=objectonly" target="object" rid-ob="figobniceng231er6tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng231er6.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng231er6.appa">appendix A</a> and the <a href="/books/NBK595311/bin/methods-pdf-11371337245.pdf">methods</a> document</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng231er6.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng231er6.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>No relevant clinical studies were identified comparing lower frequencies and duration of endoscopic surveillance or no surveillance with surveillance according to current guideline recommendations.</p><p>See also the study selection flow chart in <a href="#niceng231er6.appc">Appendix C</a>.</p></div><div id="niceng231er6.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See the excluded studies list in <a href="#niceng231er6.appe">Appendix E</a>.</p></div></div><div id="niceng231er6.s1.1.5"><h4>1.1.5. Summary of the effectiveness evidence</h4><p>There was no clinical evidence found.</p></div><div id="niceng231er6.s1.1.6"><h4>1.1.6. Economic evidence</h4><div id="niceng231er6.s1.1.6.1"><h5>1.1.6.1. Included studies</h5><p>No health economic studies were included.</p></div><div id="niceng231er6.s1.1.6.2"><h5>1.1.6.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng231er6.appd">Appendix D</a>.</p></div></div><div id="niceng231er6.s1.1.7"><h4>1.1.7. Summary of included economic evidence</h4><p>There was no economic evidence found.</p></div><div id="niceng231er6.s1.1.8"><h4>1.1.8. Economic model</h4><p>This area was given a high priority for new cost-effectiveness analysis. However, original economic modelling was not conducted due to a lack of clinical evidence.</p></div><div id="niceng231er6.s1.1.9"><h4>1.1.9. Unit costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng231er6tab2"><a href="/books/NBK595311/table/niceng231er6.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng231er6tab2" rid-ob="figobniceng231er6tab2"><img class="small-thumb" src="/books/NBK595311/table/niceng231er6.tab2/?report=thumb" src-large="/books/NBK595311/table/niceng231er6.tab2/?report=previmg" alt="Table 2. Unit costs." /></a><div class="icnblk_cntnt"><h4 id="niceng231er6.tab2"><a href="/books/NBK595311/table/niceng231er6.tab2/?report=objectonly" target="object" rid-ob="figobniceng231er6tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Unit costs. </p></div></div></div><div id="niceng231er6.s1.1.10"><h4>1.1.10. The committee’s discussion and interpretation of the evidence</h4><div id="niceng231er6.s1.1.10.1"><h5>1.1.10.1. The outcomes that matter most</h5><p>The outcomes considered for this review were health related quality of life, progression to high grade dysplasia or cancer, mortality, adverse events / complications, physician and patient adherence to surveillance. For purposes of decision making, all outcomes are considered equally important and were therefore rated as critical by the committee. No evidence was identified for any of the outcomes.</p></div><div id="niceng231er6.s1.1.10.2"><h5>1.1.10.2. The quality of the evidence</h5><p>No relevant clinical studies were identified comparing a different frequency and duration of endoscopic surveillance to the recommended ranges for surveillance given in current guidelines. Studies were commonly excluded because they were for a population not specified within the review protocol such as people with dysplasia, or they compared surveillance that did not match current guidelines as specified in the protocol to no surveillance.</p></div><div id="niceng231er6.s1.1.10.3"><h5>1.1.10.3. Benefits and harms</h5><p>The committee noted there was no evidence to recommend endoscopic surveillance that is of lower frequency compared to the current frequency recommended in guidelines or to support a definitive optimal frequency and duration. Based on their clinical experience and in line with the British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus, the committee agreed the frequency and duration of surveillance should be determined according to the individual patient’s risk factors. The committee noted the frequency of endoscopic surveillance as recommended in the BSG guidelines would be appropriate as the risk of disease progression may vary between individuals. Currently the frequency of surveillance is 2-3 years for people with Barrett’s oesophagus segment 3cm or longer, and 3-5 years for people with Barrett’s oesophagus shorter than 3cm with intestinal metaplasia. The committee agreed the main risk factors included Barrett’s segment size, age, gender, smoking status, and family history. In contrast to the BSG guideline, the European and US guidelines recommend a lower frequency of surveillance that is, 5 years for short segment and 3 years for long segment. The committee noted that surveillance according to the BSG guidelines is current practice across the UK and it would not be appropriate to recommend a lower frequency of surveillance given the lack of evidence to support such a change. In line with the BSG guidelines, the committee agreed that people with short-segment (less than 3 cm) Barrett’s oesophagus and no intestinal metaplasia (confirmed at 2 endoscopies), should not be offered surveillance as the risk of disease progression is low and the any potential benefit of surveillance does not outweigh the risks involved.</p><p>The committee considered the various factors that can influence the decision to recommend different frequencies of surveillance for each patient, which include age, co-morbidities, and the fitness of the patient for repeated invasive procedures.</p><p>The committee discussed age as a risk factor for disease progression which was hence considered a factor determining the appropriate duration of surveillance. The committee noted that the European guidelines advise against surveillance for people above the age of 75 whereas the BSG guidelines do not include an age cut-off but suggest ongoing surveillance based on an individual’s clinical assessment. When discussing the duration of endoscopic surveillance, the committee agreed with the view of the BSG, arguing that an age-related threshold failed to recognise the heterogeneity of the population and the multitude of other factors that determine fitness for endoscopy. The committee agreed that surveillance should continue for as long as it was in the patient’s interests, the benefits of surveillance outweigh any potential risks, and that this decision should be part of the ongoing patient/clinician discussion. They agreed that an important factor to consider would be the suitability of treatments involved in the entire endoscopic care pathway, which include endoscopy and intensive endoscopic treatment. Suitability should be based on a clinical assessment of the individual’s general health that will determine the trade-off between the benefits and risks of undergoing the endoscopic pathway.</p></div><div id="niceng231er6.s1.1.10.4"><h5>1.1.10.4. Cost effectiveness and resource use</h5><p>In general, more frequent surveillance will be more costly but would potentially provide more health gain if more cancers are detected and treated early.</p><p>There were no published economic evaluations found. In the absence of suitable clinical evidence, cost-effectiveness modelling was not feasible.</p><p>The committee’s decision to recommend offering:
|
|
<ul><li class="half_rhythm"><div>endoscopic surveillance every 2-3 years to people with long-segment Barrett’s oesophagus and</div></li><li class="half_rhythm"><div>every 3-5 years to people with short-segment Barrett’s oesophagus with intestinal metaplasia</div></li></ul></p><p>Reflects current practice and is therefore unlikely to have a substantial impact on resource.</p><p>The committee also made a research recommendation to assess clinical and molecular biomarkers that can inform the optimal interval of and time for discharge from endoscopic surveillance. The cost associated with such biomarkers would lead to an increase in NHS resource use: the costs of the new technologies and associated staff time to conduct the tests. However, it would allow surveillance to be targeted on those patients that would most benefit, which could lead to more efficient use of resources. The impact of such technologies should be subject to cost effectiveness analysis.</p></div><div id="niceng231er6.s1.1.10.5"><h5>1.1.10.5. Other factors the committee took into account</h5><p>The committee emphasised they were aware of ongoing studies looking at clinical and molecular biomarkers for risk stratification of Barrett’s oesophagus. They noted that evidence of biomarkers associated with a greater risk of progression of dysplasia or cancer could inform the appropriate frequency and duration of endoscopic surveillance and decided to make a recommendation for research in this area.</p></div></div><div id="niceng231er6.s1.1.11"><h4>1.1.11. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.3.3 to 1.3.5 and the research recommendation on frequency and duration of endoscopic surveillance techniques.</p></div><div id="niceng231er6.s1.1.rl.r1"><h4>1.1.12. References</h4><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng231er6.s1.1.ref1">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated January
|
|
2022]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a></div></dd></dl></dl></div></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng231er6.appa"><h3>Appendix A. Review protocols</h3><p id="niceng231er6.appa.et1"><a href="/books/NBK595311/bin/niceng231er6-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for frequency and duration of endoscopic surveillance</a><span class="small"> (PDF, 172K)</span></p><p id="niceng231er6.appa.et2"><a href="/books/NBK595311/bin/niceng231er6-appa-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Health economic review protocol</a><span class="small"> (PDF, 145K)</span></p></div><div id="niceng231er6.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng231er6.s1.1.ref1" rid="niceng231er6.s1.1.ref1"><sup>1</sup></a></p><p>For more information, please see the Methodology review published as part of the accompanying documents for this guideline.</p><p id="niceng231er6.appb.et1"><a href="/books/NBK595311/bin/niceng231er6-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1. Clinical search literature search strategy</a><span class="small"> (PDF, 135K)</span></p><p id="niceng231er6.appb.et2"><a href="/books/NBK595311/bin/niceng231er6-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.2. Health Economics literature search strategy</a><span class="small"> (PDF, 121K)</span></p></div><div id="niceng231er6.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng231er6.appc.et1"><a href="/books/NBK595311/bin/niceng231er6-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. Flow chart of clinical study selection for the review of: frequency and duration of endoscopic surveillance techniques</a><span class="small"> (PDF, 65K)</span></p></div><div id="niceng231er6.appd"><h3>Appendix D. Economic evidence study selection</h3><p id="niceng231er6.appd.et1"><a href="/books/NBK595311/bin/niceng231er6-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (160K)</span></p></div><div id="niceng231er6.appe"><h3>Appendix E. Excluded studies</h3><div id="niceng231er6.appe.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng231er6appetab1"><a href="/books/NBK595311/table/niceng231er6.appe.tab1/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng231er6appetab1" rid-ob="figobniceng231er6appetab1"><img class="small-thumb" src="/books/NBK595311/table/niceng231er6.appe.tab1/?report=thumb" src-large="/books/NBK595311/table/niceng231er6.appe.tab1/?report=previmg" alt="Table 5. Studies excluded from the clinical review." /></a><div class="icnblk_cntnt"><h4 id="niceng231er6.appe.tab1"><a href="/books/NBK595311/table/niceng231er6.appe.tab1/?report=objectonly" target="object" rid-ob="figobniceng231er6appetab1">Table 5</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng231er6.appe.s2"><h4>Health Economic studies</h4><p>Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2006 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.</p><p>None.</p></div></div><div id="niceng231er6.appf"><h3>Appendix F. Research recommendation</h3><div id="niceng231er6.appf.s1"><h4>Frequency and duration of endoscopic surveillance</h4><p>What is the usefulness of clinical and molecular biomarkers to inform the optimal frequency and duration of endoscopic surveillance for adults with Barrett’s oesophagus?</p><div id="niceng231er6.appf.s1.1"><h5>Why this is important</h5><p>Barrett’s surveillance is currently performed at 2–5-year intervals in patients who are deemed to potentially benefit from surveillance. This interval is based on consensus opinion rather than evidence, although it is to some extent tailored according to known clinical determinants of progression. The length of Barrett’s oesophagus appears to be the strongest risk factor for progression (<3cm, lower risk vs 3cm or longer, higher risk), but other clinical risk factors for oesophageal cancer have been described, including male gender, increasing age, positive family history and smoking status. If further factors associated with a greater risk of progression of non-dysplastic Barrett’s are identified and a stronger association between already identified factors and risk of progression is established through research, this would allow more precise individual tailoring of follow-up intervals, reducing frequency in those at low risk and intensifying it in those at high risk.</p></div><div id="niceng231er6.appf.s1.2"><h5>Rationale for research recommendation</h5><p id="niceng231er6.appf.et1"><a href="/books/NBK595311/bin/niceng231er6-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (64K)</span></p></div><div id="niceng231er6.appf.s1.3"><h5>Modified PICO table</h5><p id="niceng231er6.appf.et2"><a href="/books/NBK595311/bin/niceng231er6-appf-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (93K)</span></p></div></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence review underpinning recommendations 1.3.3 to 1.3.5 and a research recommendation in the NICE guideline</p><p>National Institute for Health and Care Excellence</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2023.</div><div class="small"><span class="label">Bookshelf ID: NBK595311</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37792979" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">37792979</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng231er6tab1"><div id="niceng231er6.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK595311/table/niceng231er6.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng231er6.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng231er6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng231er6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Inclusion: Adults, 18 years and over, with non-dysplastic Barrett’s oesophagus</p>
|
|
<p>Exclusion: Adults with any level of dysplasia or indefinite dysplasia</p>
|
|
</td></tr><tr><th id="hd_b_niceng231er6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng231er6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Lower frequencies of:
|
|
<ul class="circle"><li class="half_rhythm"><div>High-resolution endoscopy</div></li><li class="half_rhythm"><div>Chromoendoscopy</div></li></ul></div></li><li class="half_rhythm"><div>No surveillance</div></li></ul></td></tr><tr><th id="hd_b_niceng231er6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison</th><td headers="hd_b_niceng231er6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Surveillance according to recommendations current ranges</td></tr><tr><th id="hd_b_niceng231er6.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng231er6.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Health related quality of life</div></li><li class="half_rhythm"><div>Progression to high grade dysplasia or cancer</div></li><li class="half_rhythm"><div>Mortality</div></li><li class="half_rhythm"><div>Adverse events / complications (bleeding, perforation, pain)</div></li><li class="half_rhythm"><div>Adherence to surveillance (physician and patient)</div></li></ul>
|
|
Time point: any time point available; no minimum follow-up</td></tr><tr><th id="hd_b_niceng231er6.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng231er6.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>RCT</div></li><li class="half_rhythm"><div>SR of RCTs</div></li><li class="half_rhythm"><div>If no RCT data is available, non-randomised studies will be considered if there is an active comparator within the study and results are based on a multi-variate analysis (adjusting for any confounder)</div></li><li class="half_rhythm"><div>Cross sectional studies</div></li></ul>
|
|
Published NMAs and IPDs will be considered for inclusion.</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng231er6tab2"><div id="niceng231er6.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Unit costs</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK595311/table/niceng231er6.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng231er6.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng231er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource</th><th id="hd_h_niceng231er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Unit costs</th><th id="hd_h_niceng231er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng231er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">diagnostic endoscopic upper gastrointestinal tract procedure with biopsy, (FE21Z)</td><td headers="hd_h_niceng231er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£554</td><td headers="hd_h_niceng231er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">National Schedule of NHS Costs. 2019/20</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng231er6appetab1"><div id="niceng231er6.appe.tab1" class="table"><h3><span class="label">Table 5</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK595311/table/niceng231er6.appe.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng231er6.appe.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ackroyd, R., Tam, W., Schoeman, M.
|
|
et al. (2004) Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery. Gastrointestinal endoscopy
|
|
59(1): 1–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/14722539" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14722539</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study does not contain an intervention relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ajumobi
|
|
A, Bahjri
|
|
K, Jackson
|
|
C
|
|
et al. (2010) Surveillance in Barrett’s esophagus: an audit of practice. Digestive diseases and sciences
|
|
55(6): 1615–1621 [<a href="https://pubmed.ncbi.nlm.nih.gov/19669878" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19669878</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Aldulaimi, D. M., Cox, M., Nwokolo, C. U.
|
|
et al. (2005) Barrett’s surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. European journal of gastroenterology & hepatology
|
|
17(9): 943–50 [<a href="https://pubmed.ncbi.nlm.nih.gov/16093872" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16093872</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Barbiere, J. M. and Lyratzopoulos, G. (2009) Cost-effectiveness of endoscopic screening followed by surveillance for Barrett’s esophagus: a review. Gastroenterology
|
|
137(6): 1869–76 [<a href="https://pubmed.ncbi.nlm.nih.gov/19840798" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19840798</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Barr, H.; Stone, N.; Rembacken, B. (2005) Endoscopic therapy for Barrett’s oesophagus. Gut
|
|
54(6): 875–84 [<a href="/pmc/articles/PMC1774518/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1774518</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15888799" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15888799</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bulamu, N. B., Chen, G., Bright, T.
|
|
et al. (2019) Preferences for Surveillance of Barrett’s Oesophagus: a Discrete Choice Experiment. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
|
|
23(7): 1309–1317 [<a href="https://pubmed.ncbi.nlm.nih.gov/30478530" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30478530</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Non-randomised study with no comparison group</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Chandan, S., Mashiana, H. S., Dhaliwal, A. J.
|
|
et al. (2020) CLINICAL APPLICABILITY OF WIDE AREA TRANSEPITHELIAL SAMPLING (WATS-3D) IN SCREENING & SURVEILLANCE OF BARRETT’S ESOPHAGUS - A SYSTEMATIC REVIEW & SENSITIVITY META-ANALYSIS. Gastrointest. Endosc. 91(6): AB395–AB396
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Conference abstract</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Codipilly, D. C., Chandar, A. K., Singh, S.
|
|
et al. (2018) The Effect of Endoscopic Surveillance in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis. Gastroenterology
|
|
154(8): 2068–2086.e5 [<a href="/pmc/articles/PMC5985204/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5985204</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29458154" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29458154</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>- Systematic review used as source of primary studies</p>
|
|
<p>- Comparator in study does not match that specified in this review protocol</p>
|
|
</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Cooper, G. S., Yuan, Z., Chak, A.
|
|
et al. (2002) Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia. Cancer
|
|
95(1): 32–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/12115314" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12115314</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Corley, D. A., Mehtani, K., Quesenberry, C.
|
|
et al. (2013) Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology
|
|
145(2): 312–9.e1 [<a href="/pmc/articles/PMC3767470/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3767470</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23673354" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23673354</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Craanen, M. E., Blok, P., Meijer, G. A.
|
|
et al. (2002) Surveillance in Barrett’s oesophagus: a critical reappraisal. Scandinavian Journal of Gastroenterology - Supplement: 4–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/12408496" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12408496</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
DeMeester, S. R. (2001) Surveillance endoscopy and follow-up for Barrett’s esophagus. Problems in General Surgery
|
|
18(2): 94–98
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ding, Y. E., Li, Y., He, X. K.
|
|
et al. (2018) Impact of Barrett’s esophagus surveillance on the prognosis of esophageal adenocarcinoma: A meta-analysis. Journal of digestive diseases
|
|
19(12): 737–744 [<a href="https://pubmed.ncbi.nlm.nih.gov/30375167" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30375167</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
El-Serag, H. B., Naik, A. D., Duan, Z.
|
|
et al. (2016) Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut
|
|
65(8): 1252–60 [<a href="https://pubmed.ncbi.nlm.nih.gov/26311716" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26311716</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Falk, G. W.; Ours, T. M.; Richter, J. E. (2000) Practice patterns for surveillance of Barrett’s esophagus in the united states. Gastrointestinal endoscopy
|
|
52(2): 197–203 [<a href="https://pubmed.ncbi.nlm.nih.gov/10922091" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10922091</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Fountoulakis
|
|
A, Zafirellis
|
|
KD, Dolan
|
|
K
|
|
et al. (2004) Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. The British journal of surgery
|
|
91(8): 997–1003 [<a href="https://pubmed.ncbi.nlm.nih.gov/15286961" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15286961</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Garside, R., Pitt, M., Somerville, M.
|
|
et al. (2006) Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technology Assessment (Winchester, England)
|
|
10(8): 1–142, iii [<a href="https://pubmed.ncbi.nlm.nih.gov/16545207" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16545207</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Gerson, L. B. and Triadafilopoulos, G. (2002) Screening for esophageal adenocarcinoma: an evidence-based approach. American Journal of Medicine
|
|
113(6): 499–505 [<a href="https://pubmed.ncbi.nlm.nih.gov/12427500" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12427500</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review does not contain factors of interest</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Grover, M., Strickland, C., Kesler, E.
|
|
et al. (2006) How should patients with Barrett’s esophagus be monitored?. Journal of Family Practice
|
|
55(3): 243–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/16510060" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16510060</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hirst, N. G., Gordon, L. G., Whiteman, D. C.
|
|
et al. (2011) Is endoscopic surveillance for non-dysplastic Barrett’s esophagus cost-effective? Review of economic evaluations. Journal of Gastroenterology & Hepatology
|
|
26(2): 247–54 [<a href="https://pubmed.ncbi.nlm.nih.gov/21261712" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21261712</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kastelein, F., van Olphen, S. H., Steyerberg, E. W.
|
|
et al. (2016) Impact of surveillance for Barrett’s oesophagus on tumour stage and survival of patients with neoplastic progression. Gut
|
|
65(4): 548–54 [<a href="https://pubmed.ncbi.nlm.nih.gov/25903690" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25903690</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparison group population does not match protocol: people with OAC from the general population; population is not a single cohort with Barrett’s oesophagus</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Macdonald, C. E.; Wicks, A. C.; Playford, R. J. (2000) Final results from 10 year cohort of patients undergoing surveillance for Barrett’s oesophagus: observational study. BMJ
|
|
321(7271): 1252–5 [<a href="/pmc/articles/PMC27527/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC27527</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11082084" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11082084</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population does not meet guideline agreed definition of Barrett’s oesophagus</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ofman, J. J., Lewin, K., Ramers, C.
|
|
et al. (2000) The economic impact of the diagnosis of dysplasia in Barrett’s esophagus. American journal of gastroenterology
|
|
95(10): 2946–2952 [<a href="https://pubmed.ncbi.nlm.nih.gov/11051373" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11051373</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- No relevant outcomes reported</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Old, O., Moayyedi, P., Love, S.
|
|
et al. (2015) Barrett’s Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. Journal of medical screening
|
|
22(3): 158–164 [<a href="https://pubmed.ncbi.nlm.nih.gov/25767103" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25767103</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Protocol and analysis plan; no extractable results</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Provenzale, D., Kemp, J. A., Arora, S.
|
|
et al. (1994) A guide for surveillance of patients with Barrett’s esophagus. American journal of gastroenterology
|
|
89(5): 670–80 [<a href="https://pubmed.ncbi.nlm.nih.gov/8172136" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8172136</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Qiao, Y., Hyder, A., Bae, S. J.
|
|
et al. (2015) Surveillance in Patients With Barrett’s Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clinical and Translational Gastroenterology
|
|
6: e131 [<a href="/pmc/articles/PMC4816094/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4816094</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26658838" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26658838</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Quera, R.; O’Sullivan, K.; Quigley, E. M. M. (2006) Surveillance in barrett’s oesophagus: Will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?. Endoscopy
|
|
38(2): 162–169 [<a href="https://pubmed.ncbi.nlm.nih.gov/16479424" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16479424</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Roberts, K. J., Harper, E., Alderson, D.
|
|
et al. (2010) Long-term survival and cost analysis of an annual Barrett’s surveillance programme. Eur J Gastroenterol Hepatol
|
|
22(4): 399–403 [<a href="https://pubmed.ncbi.nlm.nih.gov/19858726" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19858726</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Royston, C., Caygill, C., Charlett, A.
|
|
et al. (2016) The evolution and outcome of surveillance of Barrett’s oesophagus over four decades in a UK District General Hospital. Eur J Gastroenterol Hepatol
|
|
28(12): 1365–1373 [<a href="https://pubmed.ncbi.nlm.nih.gov/27571366" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27571366</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rubenstein
|
|
JH, Sonnenberg
|
|
A, Davis
|
|
J
|
|
et al. (2008) Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointestinal endoscopy
|
|
68(5): 849–855 [<a href="/pmc/articles/PMC3481546/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3481546</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18547567" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18547567</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Rubenstein, J. H. and Inadomi, J. M. (2021) Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma. Gastrointestinal endoscopy clinics of North America
|
|
31(1): 77–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/33213801" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33213801</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Shaheen, N. J.; Provenzale, D.; Sandler, R. S. (2002) Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. American journal of gastroenterology
|
|
97(6): 1319–27 [<a href="https://pubmed.ncbi.nlm.nih.gov/12094844" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12094844</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Shen, E. F., Gladstone, S., Milne, G.
|
|
et al. (2003) Endoscopic surveillance practice for Barrett’s oesophagus in Scotland and early experience in implementing local guidelines. Scottish Medical Journal
|
|
48(2): 43–45 [<a href="https://pubmed.ncbi.nlm.nih.gov/12774594" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12774594</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- No relevant outcomes reported</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Singh, R.; Ragunath, K.; Jankowski, J. (2007) Barrett’s Esophagus: Diagnosis, Screening, Surveillance, and Controversies. Gut & Liver
|
|
1(2): 93–100 [<a href="/pmc/articles/PMC2871632/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2871632</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20485625" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20485625</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Theron, B. T., Padmanabhan, H., Aladin, H.
|
|
et al. (2016) The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett’s oesophagus cohort. United european gastroenterology journal
|
|
4(6): 754–761 [<a href="/pmc/articles/PMC5386229/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5386229</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28408992" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28408992</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">-Study does not contain an intervention relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
van Sandick, J. W., van Lanschot, J. J., Kuiken, B. W.
|
|
et al. (1998) Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut
|
|
43(2): 216–22 [<a href="/pmc/articles/PMC1727211/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1727211</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10189847" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10189847</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Verbeek, R. E., Leenders, M., Ten Kate, F. J.
|
|
et al. (2014) Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol
|
|
109(8): 1215–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/24980881" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24980881</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vissapragada, R., Bulamu, N. B., Brumfitt, C.
|
|
et al. (2021) Improving cost-effectiveness of endoscopic surveillance for Barrett’s esophagus by reducing low-value care: a review of economic evaluations. Surgical endoscopy
|
|
26: 26 [<a href="https://pubmed.ncbi.nlm.nih.gov/34312726" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34312726</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Vogt, J. S., Larsen, A. C., Sommer, T.
|
|
et al. (2018) Quality of endoscopic surveillance of Barrett’s esophagus. Scandinavian journal of gastroenterology
|
|
53(3): 256–259 [<a href="https://pubmed.ncbi.nlm.nih.gov/29361878" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29361878</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Population not relevant to this review protocol <i>includes dysplastic Barrett’s</i></td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wani, S. and Sharma, P. (2006) The rationale for screening and surveillance of Barrett’s metaplasia. Best Practice & Research in Clinical Gastroenterology
|
|
20(5): 829–42 [<a href="https://pubmed.ncbi.nlm.nih.gov/16997164" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16997164</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Wong, T.; Tian, J.; Nagar, A. B. (2010) Barrett’s surveillance identifies patients with early esophageal adenocarcinoma. American Journal of Medicine
|
|
123(5): 462–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/20399324" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20399324</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Comparator in study does not match that specified in this review protocol</td></tr><tr><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Yang, Y., Chen, H. N., Wang, R.
|
|
et al. (2015) Cost-Effectiveness Analysis on Endoscopic Surveillance Among Western Patients With Barrett’s Esophagus for Esophageal Adenocarcinoma Screening. Medicine
|
|
94(39): e1105 [<a href="/pmc/articles/PMC4616820/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4616820</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26426603" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26426603</span></a>]
|
|
</td><td headers="hd_h_niceng231er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Systematic review used as source of primary studies</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|